Prognosis and treatment differences between initial and second primary chondrosarcoma

Mao,Weipu; Kong,Minghao; Yu,Haiyang; Wang,Dongyan; Huang,Xin; Yao,Xudong; Fan,Jie; Geng,Jiang

doi:10.3892/ol.2019.10329

Prognosis and treatment differences between initial and second primary chondrosarcoma

Authors:
- Weipu Mao
- Minghao Kong
- Haiyang Yu
- Dongyan Wang
- Xin Huang
- Xudong Yao
- Jie Fan
- Jiang Geng
View Affiliations

Affiliations: Department of General Practice, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, P.R. China, Department of Emergency, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, P.R. China, Department of Orthopedics, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, P.R. China, Department of Urology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, P.R. China, Department of Pathology, Huashan Hospital, Fudan University School of Medicine, Shanghai 200040, P.R. China
Published online on: May 7, 2019 https://doi.org/10.3892/ol.2019.10329
Pages: 207-218
Copyright: © Mao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Prognosis and treatment differences between initial and second primary chondrosarcoma (pCS) remain unknown. In the present study, patients with chondrosarcoma diagnosed between January 2004 and December 2015 were identified using the Surveillance Epidemiology and End Results database. Kaplan‑Meier curves and log‑rank tests were used to assess overall survival (OS) and cancer‑specific survival. Univariable and multivariable Cox regression analyses were used to determine factors associated with all‑cause mortality and cancer‑specific mortality. In total, 1,655 eligible patients were included in the cohort of the present study, of which, 1,455 (87.9%) had initial pCS and 200 (12.1%) had second pCS. Patients with second pCS were more frequently diagnosed in the age range of 61‑80 years compared with patients with initial pCS (52.5 vs. 43.1%; P<0.001). The OS rate of patients with initial pCS was significantly higher than that of patients with second pCS (78.3 vs. 63.0%; P<0.001). Multivariable logistic regression analyses suggested that second pCS predicted higher all‑cause mortality (hazard ratio, 1.72; 95% confidence interval, 1.31‑2.26, P<0.001) compared with that in patients with initial pCS. Furthermore, there were no differences observed in the treatment benefits between the patients with initial and second pCS. In conclusion, second pCS was more frequently diagnosed in older patients compared with initial pCS. In addition, the prognosis of patients with second pCS was worse than that of patients with initial pCS, and the treatment is essentially the same for initial and second pCS.

View Figures

View References

1	Wagner MJ, Ricciotti RW, Mantilla J, Loggers ET, Pollack SM and Cranmer LD: Response to PD1 inhibition in conventional chondrosarcoma. J Immunother Cancer. 6:942018. View Article : Google Scholar : PubMed/NCBI
2	Chen JC, Huang C, Lee IN, Wu YP and Tang CH: Amphiregulin enhances cell migration and resistance to doxorubicin in chondrosarcoma cells through the MAPK pathway. Mol Carcinog. 57:1816–1824. 2018. View Article : Google Scholar : PubMed/NCBI
3	Sangma MM and Dasiah S: Chondrosarcoma of a rib. Int J Surg Case Rep. 10:126–128. 2015. View Article : Google Scholar : PubMed/NCBI
4	Murphey MD, Walker EA, Wilson AJ, Kransdorf MJ, Temple HT and Gannon FH: From the archives of the AFIP: Imaging of primary chondrosarcoma: Radiologic-pathologic correlation. Radiographics. 23:1245–1278. 2003. View Article : Google Scholar : PubMed/NCBI
5	Aigner T: Towards a new understanding and classification of chondrogenic neoplasias of the skeleton-biochemistry and cell biology of chondrosarcoma and its variants. Virchows Arch. 441:219–230. 2002. View Article : Google Scholar : PubMed/NCBI
6	Schoenfeld AJ, Hornicek FJ, Pedlow FX, Kobayashi W, Raskin KA, Springfield D, DeLaney TF, Nielsen GP, Mankin HJ and Schwab JH: Chondrosarcoma of the mobile spine: A review of 21 cases treated at a single center. Spine (Phila Pa 1976). 37:119–126. 2012. View Article : Google Scholar : PubMed/NCBI
7	Staals EL, Bacchini P and Bertoni F: Dedifferentiated central chondrosarcoma. Cancer. 106:2682–2691. 2006. View Article : Google Scholar : PubMed/NCBI
8	Grimer RJ, Gosheger G, Taminiau A, Biau D, Matejovsky Z, Kollender Y, San-Julian M, Gherlinzoni F and Ferrari C: Dedifferentiated chondrosarcoma: Prognostic factors and outcome from a European group. Eur J Cancer. 43:2060–2065. 2007. View Article : Google Scholar : PubMed/NCBI
9	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
10	Liu L, de Vries E, Louwman M, Aben K, Janssen-Heijnen M, Brink M, Coebergh JW and Soerjomataram I: Prevalence of multiple malignancies in the Netherlands in 2007. Int J Cancer. 128:1659–1667. 2011. View Article : Google Scholar : PubMed/NCBI
11	Cheng HY, Chu CH, Chang WH, Hsu TC, Lin SC, Liu CC, Yang AM and Shih SC: Clinical analysis of multiple primary malignancies in the digestive system: A hospital-based study. World J Gastroenterol. 11:4215–4219. 2005. View Article : Google Scholar : PubMed/NCBI
12	Chrouser K, Leibovich B, Bergstralh E, Zincke H and Blute M: Bladder cancer risk following primary and adjuvant external beam radiation for prostate cancer. J Urol. 174:107–110. 2005. View Article : Google Scholar : PubMed/NCBI
13	Brumback RA, Gerber JE, Hicks DG and Strauchen JA: Adenocarcinoma of the stomach following irradiation and chemotherapy for lymphoma in young patients. Cancer. 54:994–998. 1984. View Article : Google Scholar : PubMed/NCBI
14	Frederick LG, Carolyn CC, April G. Fritz CTR, Jatin PS and David PW: AJCC Cancer Staging Atlas. Springer Berlin. 2012.
15	Martin AM, Cagney DN, Catalano PJ, Warren LE, Bellon JR, Punglia RS, Claus EB, Lee EQ, Wen PY, Haas-Kogan DA, et al: Brain metastases in newly diagnosed breast cancer: A population-based study. JAMA Oncol. 3:1069–1077. 2017. View Article : Google Scholar : PubMed/NCBI
16	Fromm J, Klein A, Baur-Melnyk A, Knösel T, Lindner L, Birkenmaier C, Roeder F, Jansson V and Dürr HR: Survival and prognostic factors in conventional central chondrosarcoma. BMC Cancer. 18:8492018. View Article : Google Scholar : PubMed/NCBI
17	Rozeman LB, Hogendoorn PC and Bovee JV: Diagnosis and prognosis of chondrosarcoma of bone. Expert Rev Mol Diagn. 2:461–472. 2002. View Article : Google Scholar : PubMed/NCBI
18	Giuffrida AY, Burgueno JE, Koniaris LG, Gutierrez JC, Duncan R and Scully SP: Chondrosarcoma in the United States (1973 to 2003): An analysis of 2890 cases from the SEER database. J Bone Joint Surg Am. 91:1063–1072. 2009. View Article : Google Scholar : PubMed/NCBI
19	Savary M, Monnier P, Pasche R, Brossard E, Pasche P and Lang F: Multiple primary malignancies. Adv Otorhinolaryngol. 46:165–175. 1991.PubMed/NCBI
20	Armstrong GT, Liu W, Leisenring W, Yasui Y, Hammond S, Bhatia S, Neglia JP, Stovall M, Srivastava D and Robison LL: Occurrence of multiple subsequent neoplasms in long-term survivors of childhood cancer: A report from the childhood cancer survivor study. J Clin Oncol. 29:3056–3064. 2011. View Article : Google Scholar : PubMed/NCBI
21	Rosso S, De Angelis R, Ciccolallo L, Carrani E, Soerjomataram I, Grande E, Zigon G and Brenner H; EUROCARE Working Group, : Multiple tumours in survival estimates. Eur J Cancer. 45:1080–1094. 2009. View Article : Google Scholar : PubMed/NCBI
22	Keller U, Grabenbauer G, Kuechler A, Sprung CN, Müller E, Sauer R and Distel L: Cytogenetic instability in young patients with multiple primary cancers. Cancer Genet Cytogenet. 157:25–32. 2005. View Article : Google Scholar : PubMed/NCBI
23	Crocetti E, Buiatti E and Falini P; Italian Multiple Primary Cancer Working Group, : Multiple primary cancer incidence in Italy. Eur J Cancer. 37:2449–2456. 2001. View Article : Google Scholar : PubMed/NCBI
24	Heo J, Noh OK, Oh YT, Chun M and Kim L: Second primary cancer after liver transplantation in hepatocellular carcinoma: A nationwide population-based study. Hepatol Int. 11:523–528. 2017. View Article : Google Scholar : PubMed/NCBI
25	Chen Q, Zhao S, Song Y, Gao P, Sun J, Chen X, Sun Y and Wang Z: Do patients with second primary colorectal cancer hold the similar prognosis and therapeutic benefits as those with initial primary colorectal cancer? Biomed Res Int. 2018:Article ID 6172670. 2018. View Article : Google Scholar